Flagship’s Cellarity maps out network-based drug discovery

Cellarity debuted Tuesday with technology to leverage single cell data to identify compounds that trigger protective changes in molecular networks, without needing to pin their therapeutic effects onto a single target.

With $50 million in funding from Flagship Pioneering, the company uses single cell technologies and machine learning to generate maps of disease-relevant molecular networks. The company’s more than 250 disease-focused “Cellarity Maps” then serve as guides to find therapies, and the right model systems to test them in...